Wall Street brokerages forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will announce $1.17 billion in sales for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The lowest sales estimate is $1.15 billion and the highest is $1.21 billion. Alexion Pharmaceuticals reported sales of $1.05 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.4%. The company is expected to issue its next quarterly earnings report on Thursday, July 25th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $4.78 billion for the current fiscal year, with estimates ranging from $4.71 billion to $4.91 billion. For the next fiscal year, analysts expect that the business will post sales of $5.44 billion, with estimates ranging from $4.86 billion to $5.98 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $1.99 by $0.40. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.68 EPS.

Several research analysts recently issued reports on the stock. BidaskClub raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Raymond James increased their target price on shares of Alexion Pharmaceuticals from $161.00 to $164.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Guggenheim reissued a “neutral” rating and set a $135.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, March 21st. Cowen restated a “buy” rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Wednesday, March 13th. Finally, TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a report on Thursday, April 25th. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $162.25.

Shares of NASDAQ:ALXN traded up $3.50 during trading on Monday, reaching $131.91. The stock had a trading volume of 65,642 shares, compared to its average volume of 1,511,350. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.36 and a current ratio of 3.87. Alexion Pharmaceuticals has a 52 week low of $92.56 and a 52 week high of $141.86. The firm has a market cap of $29.37 billion, a P/E ratio of 18.58, a P/E/G ratio of 0.99 and a beta of 1.53.

Several hedge funds have recently made changes to their positions in ALXN. Covenant Partners LLC bought a new position in Alexion Pharmaceuticals during the first quarter valued at about $502,000. CWM Advisors LLC grew its position in Alexion Pharmaceuticals by 19.3% during the first quarter. CWM Advisors LLC now owns 6,922 shares of the biopharmaceutical company’s stock valued at $936,000 after buying an additional 1,118 shares during the period. HighTower Advisors LLC grew its position in Alexion Pharmaceuticals by 4.1% during the first quarter. HighTower Advisors LLC now owns 4,618 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 181 shares during the period. Sio Capital Management LLC grew its position in Alexion Pharmaceuticals by 108.4% during the first quarter. Sio Capital Management LLC now owns 35,421 shares of the biopharmaceutical company’s stock valued at $4,788,000 after buying an additional 18,421 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in Alexion Pharmaceuticals by 5.9% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,917 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 218 shares during the period. Institutional investors own 94.82% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: Moving Average (MA)

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.